STAT+: Trump most-favored nation drug pricing deals end after three years for some companies

STAT News · Feb 27, 2026 · Collected from RSS

Summary

SEC filings show that, at least for some drugmakers, "most-favored nation" drug pricing deals with President Trump last three years.

Full Article

WASHINGTON — President Trump often brags that the “most-favored nation” deals he struck with drugmakers have set the country on a new path to no longer paying more than its fair share for prescription drug costs. But many details of the agreements haven’t been released by the administration and the companies, including their duration. Now STAT has learned from Securities and Exchange Commission filings that, at least for some of the companies, those deals last three years. The agreements vary by each of the 16 companies that have struck them, but there are several commonalities. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+. Already have an account? Log in View All Plans To read the rest of this story subscribe to STAT+. Subscribe

Share this story

Read Original at STAT News

STAT Newsabout 12 hours ago

STAT+: Pharmalittle: We’re reading about FDA and a ‘smear campaign,’ Cigna buying a large pharmacy, and more

FDA Commissioner Marty Makary defended the agency’s recent rejections of rare disease drugs and top agency official Vinay Prasad

STAT News1 day ago

STAT+: FDA Commissioner Marty Makary defends rare disease drug rejections, Vinay Prasad

FDA Commissioner Marty Makary defended the agency’s recent rejections of rare disease drugs and one of his deputies, Vinay Prasad, in an interview with CNBC.

STAT News1 day ago

STAT+: FDA rejection is a reality check on agency rhetoric

Sarepta CEO steps down, an experimental cell therapy rejection, and more biotech news

STAT News1 day ago

STAT+: Pharmalittle: We’re reading about a puzzling FDA rejection, a Lilly weight loss pill, and more

An experimental therapy for a rare blood cancer was rejected by the FDA though internal reviewers had recommended it be cleared

STAT News1 day ago

STAT+: Rare disease advocates fume over FDA’s mixed signals

Families facing rare diseases feel whiplash over shifting and contradictory decisions by the FDA.

STAT News2 days ago

STAT+: A rare disease drug was approvable, then it wasn’t. Inside a surprise rejection by the FDA

Drugmakers thought they had the FDA's buy-in to approve a therapy to treat a type of cancer that can quickly turn deadly. The agency, however, rejected it.

STAT+: Trump most-favored nation drug pricing deals end after three years for some companies

Full Article

Related Articles

STAT+: Pharmalittle: We’re reading about FDA and a ‘smear campaign,’ Cigna buying a large pharmacy, and more

STAT+: FDA Commissioner Marty Makary defends rare disease drug rejections, Vinay Prasad

STAT+: FDA rejection is a reality check on agency rhetoric

STAT+: Pharmalittle: We’re reading about a puzzling FDA rejection, a Lilly weight loss pill, and more

STAT+: Rare disease advocates fume over FDA’s mixed signals

STAT+: A rare disease drug was approvable, then it wasn’t. Inside a surprise rejection by the FDA

STAT+: Trump most-favored nation drug pricing deals end after three years for some companies

Full Article

Related Articles

STAT+: Pharmalittle: We’re reading about FDA and a ‘smear campaign,’ Cigna buying a large pharmacy, and more

STAT+: FDA Commissioner Marty Makary defends rare disease drug rejections, Vinay Prasad

STAT+: FDA rejection is a reality check on agency rhetoric

STAT+: Pharmalittle: We’re reading about a puzzling FDA rejection, a Lilly weight loss pill, and more

STAT+: Rare disease advocates fume over FDA’s mixed signals

STAT+: A rare disease drug was approvable, then it wasn’t. Inside a surprise rejection by the FDA

Related Articles

STAT Newsabout 12 hours ago
STAT+: Pharmalittle: We’re reading about FDA and a ‘smear campaign,’ Cigna buying a large pharmacy, and more
FDA Commissioner Marty Makary defended the agency’s recent rejections of rare disease drugs and top agency official Vinay Prasad

STAT News1 day ago
STAT+: FDA Commissioner Marty Makary defends rare disease drug rejections, Vinay Prasad
FDA Commissioner Marty Makary defended the agency’s recent rejections of rare disease drugs and one of his deputies, Vinay Prasad, in an interview with CNBC.

STAT News1 day ago
STAT+: FDA rejection is a reality check on agency rhetoric
Sarepta CEO steps down, an experimental cell therapy rejection, and more biotech news

STAT News1 day ago
STAT+: Pharmalittle: We’re reading about a puzzling FDA rejection, a Lilly weight loss pill, and more
An experimental therapy for a rare blood cancer was rejected by the FDA though internal reviewers had recommended it be cleared

STAT News1 day ago
STAT+: Rare disease advocates fume over FDA’s mixed signals
Families facing rare diseases feel whiplash over shifting and contradictory decisions by the FDA.

STAT News2 days ago
STAT+: A rare disease drug was approvable, then it wasn’t. Inside a surprise rejection by the FDA
Drugmakers thought they had the FDA's buy-in to approve a therapy to treat a type of cancer that can quickly turn deadly. The agency, however, rejected it.